Role of neopterin and 7,8-dihydroneopterin in human immunodeficiency virus infection: Marker for disease progression and pathogenic link

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue 2, 1996, Pages 184-193

  Baier Bitterlich, Gabriele ^a   Wachter, Helmut ^a   Fuchs, Dietmar ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

7,8 Dihydroneopterin; AIDS; Apoptosis; HIV replication; Human immunodeficiency virus; Neopterin; Reactive oxygen intermediates

Indexed keywords

NEOPTERIN;

APOPTOSIS; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; T LYMPHOCYTE; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029824131     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199610010-00010     Document Type: Article

References (98)

1. Wachter H, Fuchs D, Hausen A, et al. Elevated urinary neopterin levels in patients with the acquired immunodeficiency syndrome. Hoppe Seylers Z Physiol Chem 1983;364:1345-6.
2. Fuchs D, Hausen A, Reibnegger G, et al. Urinary neopterin in the diagnosis of acquired immune deficiency syndrome. Eur J Clin Microbiol 1984;3:70-1.
3. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988;9:150-5.
4. Fuchs D, Spira TJ, Hausen A, et al. Neopterin as predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem 1989;35:1746-9.
5. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
6. Kern P, Rokos H, Dietrich M. Raised serum neopterin levels and imbalances of T-lymphocyte subsets in viral diseases, acquired immune deficiency and related lymphadenopathy syndromes. Biomed Pharmacother 1984;38:407-11.
7. Fuchs D, Banekovich M, Hausen A, et al. Neopterin estimation compared with the ratio of T-cell subpopulations in persons infected with human immunodeficiency virus-1. Clin Chem 1988;34:2415-7.
8. Prince HE, Kleinman S, Czaplicki C, John J, Williams AE. Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection. J Acquir Immune Defic Syndr 1990;3:525-30.
9. Krämer A, Wiktor SZ, Fuchs D, et al. Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection. J Acquir Immune Def Syndr 1989;2:291-6.
10. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as a marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989;27:81-141.
11. Wachter H, Fuchs D, Hausen A, et al. Neopterin. Berlin: Walter de Gruyter, 1992.
12. Weiss G, Fuchs D, Hausen A, et al. Neopterin modulates toxicity by reactive oxygen and chloride species. FEBS Lett 1993;321:89-92.
13. Kojima S, Nomura T, Icho T, Kajiwara Y, Kitabatake K, Kubota K. Inhibitory effect of neopterin on NADPH-dependent superoxide-generating oxidase of rat peritoneal macrophages. FEBS Lett 1993;329:125-8.
14. Murr C, Fuchs D, Gössler W, et al. Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 1994;338:223-6.
15. Reibnegger G, Fuchs D, Murr C, Dierich MP, Pfleiderer W, Wachter H. Effects of pteridines on luminol-dependent chemiluminescence induced by chloramine-T. Free Rad Biol Med 1995;18:515-23.
16. Fuchs D, Gruber A, Überall F, Wachter H. Oxidative stress and apoptosis. Immunol Today 1994;15:496
17. Baier-Bitterlich G, Fuchs D, Murr C, et al. Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-α induced programmed cell death. FEBS Lett 1995;364:234-8.
18. Nathan CF. Secretory products of macrophages. J Clin Invest 1987;79:319-26.
19. Billiau A, Dijkmans R. Interferon-gamma: mechanisms of action and therapeutic potential. Biochem Pharmacol 1990;40:1433-9.
20. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. J Exp Med 1984;160:310-6.
21. Bitterlich G, Szabo G, Werner ER, et al. Selective induction of mononuclear phagocytes to produce neopterin by interferons. Immunobiology 1988;176:228-35.
22. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Wachter H. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-γ. Biochem J 1989;262:861-6.
23. Werner-Felmayer, Werner ER, Fucho D, et al. Pteridine biosynthesis in human endothelial cells. J Biol Chem 1993;268:1842-6.
24. Werner ER, Werner-Felmayer G, Fuchs D, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1 and T24 cells. J Biol Chem 1990;265:3189-92.
25. Fuchs D, Malkovsky M, Reibnegger G, Werner ER, Forni G, Wachter H. Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation, Immunol Lett 1989;23:103-8.
26. Fan J, Bass HZ, Fahey JL. Elevated IFN-γ and decreased IL-2 gene expression are associated with HIV infection. J Immunol 1993;151:5031.
27. Denz H, Fuchs D, Hausen A, et al. Value of urinary neopterin in the differential diagnosis of bacterial and viral infections. Klin Wochenschr 1990;68:218-22.
28. Fuchs D, Milstien S, Krämer A, et al. Urinary neopterin concentrations vs total neopterins for clinical utility. Clin Chem 1989;35:2305-7.
29. Levine RA, Milstien S. The ratio of reduced to oxidized neopterin and biopterin in human fluids: significance to the study of human disease. In: Pfleiderer W, Wachter H, Curtius H-C, eds. Biochemical and clinical aspects of pteridines, vol. 3. Berlin: Walter de Gruyter, 1984;277-84.
30. Fuchs D, Werner ER, Wachter H. Soluble products of immune activation: neopterin. In: Rose NR, deMacario EC, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical laboratory immunology. Washington, D.C.: American Society of Microbiology, 1992:251-5.
31. Fuch D, Stahl-Henning C, Gruber A, et al. Neopterin - its clinical use in urinanalysis. Kidney Intern 1994;46:8-11.
32. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science 1983;220:868-71.
33. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk of AIDS. Science 1984;224:500-3.
34. Evans LA, Levy JA. HIV Molecular organization. In: Morrow WJW, Haigwood NL, eds. Pathogenicity and treatment. Amsterdam: Elsevier, 1993:29-73.
35. Pantaleo G, Grazioso C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-35.
36. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011-8.
37. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993;57:183-289.
38. Daar ES, Moudgil T, Meyer RD, Ho-DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-4.
39. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma in patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
40. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
41. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
42. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
43. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988;239:617-22.
44. Rosenberg ZF, Fauci AS. Fundamental immunology 3rd ed. New York: Raven Press, 1989:00-00. (Advances in immunology; vol. 00).
45. Rosenberg ZF, Fauci AS. Fundamental immunology 3rd ed. New York: Raven Press, 1989:00-00. (Advances in immunology; vol. 00).
46. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation and continuous production of cytopathic retroviruses (HTLV III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
47. Zagury D, Bernard J, Leonard R, et al. Long-term cultures of HTLV-III-infected T-cells: a model of cytopathology of T-cell depletion in AIDS. Science 1986;231:850-3.
48. Gougeon ML, Montagnier L. Apoptosis in AIDS. Science 1993;260:1269-70.
49. Fuchs D, Hausen A, Reibnegger G, et al. Interferon-γ concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1. J Acquir Immune Def Syndr 1989;2:158-62.
50. Zangerle R, Gallati H, Sarcletti M, et al. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation, J Acquir Immune Def Syndr 1994;7:79-85.
51. Zangerle R, Schönitzer D, Fuchs D, Möst J, Dierich MP, Wachter H. Reducing HIV transmission by seronegative blood. Lancet 1992;339:130-1.
52. Gaines H, von Sydow MA, von Stedingk LV, et al. Immunological changes in primary HIV-1 infection. AIDS 1990;4:995-9.
53. Melmed RN, Taylor JM, Detels R, Bozorgmehri M, Fahey JL. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J Acquir Immune Defic Syndr 1989;2:70-6.
54. Fuchs D, Albert J, Asjö B, Fenyö M, Reibnegger G, Wachter H. Association between serum neopterin concentrations and in vitro replicative capacity of HIV-1 isolates. J Infect Dis 1989;160:724-5.
55. Fuchs D, Hausen A, Reibnegger G, et al. Cancer Detect Prevent 1987;1(suppl):535.
56. Hutterer J, Fuchs D, Eder G, et al. Neopterin as discriminating and prognostic parameter in healthy homosexuals, ARC and AIDS patients. Wien Klin Wochenschr 1987;99:531-5.
57. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993;7:1159-66.
58. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990;28:556-60.
59. Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 1991;41:69-74.
60. Reibnegger R, Fuchs D, Hausen A, Schmutzhard E, Werner ER, Wachter H. The dependence of cell-mediated immune activation in malaria on age and endemicity. Trans R Soc Trop Med Hyg 1987;81:729-33.
61. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Who will get AIDS? Lancet 1986;2:1216.
62. Munoz A, Vlahov D, Solomon L, et al. Prognostic indicators for development of AIDS among intravenous drug users. J Acquir Immune Defic Syndr 1992;5:694-700.
63. Crocchiolo PR, Lizioli A, Cantaluppi P, et al. CD4+: neopterin ratio correlates with p24 antigenaemia in HIV infected patients. J Clin Lab Immunol 1990;31:55-7.
64. Ellaurie M, Calvelli T, Rubinstein A. Neopterin concentrations in pediatric human immunodeficiency virus infection as predictor of disease activity. Pediatr Infect Dis J 1992;11:286-9.
65. Strickler HD, Blanchard JF, Vlahov D, et al. Elevated serum levels of neopterin but not beta 2-microglobulin in HIV-1-seronegative injecting drug users. AIDS 1993;7:361-7.
66. Bass HZ, Hardy WD, Mitsuyasu RT, et al. The effect of zidovudine treatment on serum neopterin and b2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals. J Acquir Immune Defic Syndr 1992;5:215-21.
67. Jacobson MA, Baccetti P, Kolokathis A, et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. Br Med J 1991;302:73-8.
68. 2-induced luminol chemiluminescence: mechanistic effects. Free Rad Biol Med (in press).
69. Heales SJR, Blair JA, Meinschad C, Ziegler I. Inhibition of monocyte luminol-dependent chemiluminescence by tetrahydrobiopterin, and the free radical oxidation of tetrahydrobiopterin, dihydrobiopterin and dihydroneopterin. Cell Biochem Funct 1988;6:191-5.
70. Kojima S, Icho T, Kajiwara Y, Kubota K. Neopterin as an endogenous antioxidant. FEBS Lett 1992;304:163-6.
71. Uberall F, Werner-Felmayer G, Schubert C, Grunicke HH, Wachter H, Fuchs D. Neopterin derivatives together with cyclic guanosine monophosphate induce c-fos gene expression. FEBS Lett 1994;352:11-4.
72. Baier-Bitterlich G, Fuchs D, Zangerle R, et al. Transactivation of the HIV-1 promoter by 7,8-dihydroneopterin. A potential role of neopterin derivatives in AIDS progression. AIDS Res Hum Retrovir (in press).
73. Schobersberger W, Hoffmann G, Grote J, Wachter H, Fuchs D. Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells. FEBS Lett 1995;377:461-4.
74. Schobersberger W, Jelkmann W, Fandrey J, Frede S, Wachter H, Fuchs D. Neopterin-induced suppression of erythropoietin production in vitro. Pteridines 1995;6:12-6.
75. Wöll E, Weiss G, Fuchs D, Lang F, Wachter H. Effect of pteridine derivatives on intracellular calcium concentration in human monocytic cells. FEBS Lett 1993;318:249-52.
76. Barak M, Gruener N. Neopterin augmentation of tumor necrosis factor production. Immunol Lett 1991;30:101-6.
77. Blair JA, Pearson AJ. A kinetic study of the autoxidation of tetrahydrobiopterin. Tetrahedron Lett 1973;3:203.
78. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 1993;12:2005-15.
79. Greenspan HC, Aruoma OI. Oxidative stress and apoptosis in HIV infection: a role for plant-derived metabolites with synergistic antioxidant activity. Immunol Today 1994;15:209-13.
80. Buttke TM, Sandstrom PA. Oxidative stress as amediator of apoptosis. Immunol Today 1994;15:7-10.
81. Laurent-Crawford AG, Krust B, Muller S, et al. The cytopathic effort of HIV is associated with apoptosis. Virology 1991;185:829-39.
82. Meyaard L, Ottok SA, Jonker RR, Mijnster MJ, Keet RP, Miedema F. Programmed death of T cells in HIV-1 infection. Science 1992;257:217-9.
83. Golstein P, Ojcius DM, Young JD-E. Cell death mechanisms and the immune system. Immunol Rev 1991;121:29-65.
84. Ameisen JC. Programmed cell death and AIDS: from hypothesis to experiment. Immunol Today 1991;13:388-91.
85. Banda NK, Bernier J, Kurahara DK, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992;176:1099-106.
86. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 1991;10:2247-58.
87. Droge W, Eck H-P, Mihm S. HIV-induced cysteine deficiency and T-cell dysfunction- a rationale for treatment with N-acetylcysteine. Immunol Today 1992;13:211-3.
88. Larrick JW, Wright SC. Cytotoxic mechanisms of tumor necrosis factor-α. FASEB J 1990;4:3215-23.
89. Wright SC, Kumar P, Tam AW, Shen N, Varma M, Larrick JW. Apoptosis and DNA fragmentation precede TNF-induced cytolysis in U937 cells. J Cell Biochem 1992;48:344-55.
90. Higuchi M, Aggarwal BB. Differential roles of two types of the TNF receptor in TNF-induced cytotoxicity, DNA fragmentation, and differentiation. J Immunol 1994;152:4017-25.
91. Sgonc R, Wick G. Methods for the detection of apoptosis. Int Arch Allergy Immunol 1994;105:327-32.
92. Hirose K, Longo DL, Oppenheim JJ, Matsushima K. Over-expression of mitochondrial manganese Superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs and ionizing radiation. FASEB J 1993;7:3618.
93. Chang DJ, Ringold GM, Heller RA. Cell killing and induetion of manganous Superoxide dismutase by tumor necrosis factor α is mediated by lipoxygenase metabolites of arachidonic acid. Biochem Biophys Res Commun 1992;188:538-46.
94. Fuchs D, Shearer GM, Boswell RN, et al. Increased serum neopterin in patients with HIV-1 infection is correlated with reduced in vitro interleukin-2 production. Clin Exp Immunol 1990;80:44-8.
95. Greene W. Regulation of HIV-1 gene expression. Annu Rev Immunol 1990;8:453-75.
96. Baeuerle PA, Baltimore D. In: Cohen P, Foulkes JG, eds. Molecular aspects of cellular regulation, hormonal control regulation of gene transcription. Amsterdam: Elsevier/ North Holland Biomedical Press, 1991:409-32.
97. Baeuerle PA. The inducible transcription activator NF-κB: regulation by distinct protein subunits. Biochim Biophys Acta 1991;1072:63-80.
98. Crawford D, Zbinden I, Amstad P, Cerutti O. Oxidant stress induces the proto-oncogenes c-fos and c-myc in mouse epidermal cells. Oncogene 1988;3:27-32.